tbuckley/cabot-search huggingface dataset:
Improved data collection is needed to support these proposals
Authors: D. J. Wilks, T. Elahi, S. K. Al-Ghazal
Journal: BMJ (2010)

<b>1207</b> <h3><b>Objectives</b></h3> Imaging modalities in epilepsy pre-surgical evaluation can significantly increase medical cost due to multiple procedures. The goal of our study is to validate the utility and analyze the cost effectiveness of each modality in order to maximize the benefit of pre-surgical assessment. <h3><b>Methods</b></h3> 16 pediatric patients (M:F= 5:11, mean age: 14) with intractable seizures which were evaluated by all imaging modalities including MRI, FDG PET, IC, IT, computerize subtraction analysis, EEG, phase 1 and phase 2 surgical grid placement and subsequent undergoing epilepsy surgery were selected retrospectively. Each patient’s imaging studies were randomized, grouped into 10 different combinations (table) and then blindly interpreted by two epilepsy imaging specialists using consensus agreement. The location of epileptogenic focus by region (lobe) and by hemisphere was recorded. Using successful surgical outcome as a reference, each combination of imaging modalities was analyzed. <h3><b>Results</b></h3> See Table. <h3><b>Conclusions</b></h3> PET is slightly better than IC-IT SPECT in performance overall. However, at a given cost, IC-IT SPECT is significantly more cost effective than PET. Therefore, PET or IC-IT SPECT should be considered as a first-line imaging
Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma
Authors: Paul A Northcott, Yukiko Nakahara, Xiaochong Wu, Lars Feuk, David W Ellison, Sid Croul, Stephen Mack, Paul N Kongkham, John Peacock, Adrian Dubuc, Young-Shin Ra, Karen Zilberberg, Jessica Mcleod, Stephen W Scherer, J Sunil Rao, Charles G Eberhart, Wiesia Grajkowska, Yancey Gillespie, Boleslaw Lach, Richard Grundy, Ian F Pollack, Ronald L Hamilton, Timothy Van Meter, Carlos G Carlotti, Frederick Boop, Darrell Bigner, Richard J Gilbertson, James T Rutka, Michael D Taylor
Journal: Nature Genetics (2009)
Duplication of Atxn1l suppresses SCA1 neuropathology by decreasing incorporation of polyglutamine-expanded ataxin-1 into native complexes
Authors: Aaron B Bowman, Yung C Lam, Paymaan Jafar-Nejad, Hung-Kai Chen, Ronald Richman, Rodney C Samaco, John D Fryer, Juliette J Kahle, Harry T Orr, Huda Y Zoghbi
Journal: Nature Genetics (2007)
Gamma-aminobutyric acid mediation of the inhibitory effect of endogenous opioids on the arginine vasopressin and oxytocin responses to nicotine from cigarette smoking
Authors: P. Chiodera, R. Volpi, L. Capretti, R. Bocchi, G. Caffarri, A. Marcato, G. Rossi, V. Coiro
Journal: Metabolism (1993)
Recombinant CUB-1 domain polypeptide inhibits the cleavage of ULVWF strings by ADAMTS13 under flow conditions
Authors: Zhenyin Tao, Yuandong Peng, Leticia Nolasco, Santiago Cal, Carlos Lopez-Otin, Renhao Li, Joel L. Moake, José A. López, Jing-fei Dong
Journal: Blood (2005)
Spider mite allergy in apple-cultivating farmers: European red mite (Panonychus ulmi) and two-spotted spider mite (Tetranychus urticae) may be important allergens in the development of work-related asthma and rhinitis symptoms☆☆☆
Authors: Yoon-Keun Kim, Myung-Hyun Lee, Young-Koo Jee, Sung-Chul Hong, Jong-Myun Bae, Yoon-Suk Chang, Jae-Won Jung, Byung-Jae Lee, Jee-Woong Son, Sang-Heon Cho
Journal: Journal of Allergy and Clinical Immunology (1999)
Coronary Vascular Responses to Stimulation of Chemoreceptors and Baroreceptors: EVIDENCE FOR REFLEX ACTIVATION OF VAGAL CHOLINERGIC INNERVATION
Authors: James G. Hackett, Francois M. Abboud, Allyn L. Mark, Phillip G. Schmid, Donald D. Heistad, Dennis Bollard, Leonard Brooks
Journal: Circulation Research (1972)

Coronary vascular responses to stimulation of chemoreceptors were studied in anesthetized, artificially ventilated dogs. The circumflex coronary artery was perfused at constant flow so that changes in perfusion pressure reflected changes in coronary resistance. Practolol, a myocardioselective beta-receptor antagonist, and pacing were used to minimize indirect effects of myocardial responses on coronary resistance. Carotid and aortic injections of nicotine produced decreases in coronary perfusion pressure averaging -21 mm Hg and -22 mm Hg, respectively. Decreases with carotid and aortic injections of cyanide averaged -8 mm Hg and -17 mm Hg, respectively. These coronary dilator responses were abolished by bilateral vagotomy or atropine. Changes in perfusion pressure with carotid injections of nicotine averaged +3 mm Hg after vagotomy and +2 mm Hg after administration of atropine. The coronary dilator responses to carotid chemoreceptor stimulation were accompanied by increases in coronary sinus Po 2 in five studies and no change in two studies. Carotid sinus nerve stimulation caused abrupt and sustained coronary vasodilatation. After vagotomy or administration of atropine, the response to carotid sinus nerve stimulation was no longer abrupt but occurred gradually, suggesting that a component of the reflex response was blocked. These studies indicate that stimulation of chemoreceptors activates a vagal cholinergic vasodilator pathway to coronary vessels in the dog. Activation of this pathway appears also to contribute to reflex coronary responses to stimulation of baroreceptors.
Abstract 940: Differential sensitivity of BRAF mutant glioma cell lines to the new oncogenic BRAF kinase inhibitor UI-152.
Authors: Michael Lee, Jun-Ho Ahn, Soon Kil Ahn, Yong W. Lee
Journal: Cancer Research (2013)

Abstract Glioblastomas are a highly aggressive and detrimental brain tumor, comprising 50% of all human gliomas. Glioblastomas have a median survival of less than two years after diagnosis because it has a high capacity for proliferation and is extremely chemoresistant. A common molecular event that characterizes glioblastoma is constitutive activation of the RAS-RAF-MAPK signaling pathway. Activating mutation of BRAF (BRAF-V600E) has been reported in a subset of these tumors. We recently developed UI-152 as the new oncogenic BRAF targeting drug. In biochemical assays, UI-152 inhibited BRAF-V600E at very low nanomolar concentrations and showed a 10-fold higher potency against BRAF-V600E than another well-known oncogenic BRAF inhibitor, PLX4032/4720. In the present study, we evaluated the individual IC50 values of UI-152 from the cell growth inhibitory effects of the six malignant glioma cell lines with different BRAF mutational status. KG-1-C, NMC-G1, and DBTRG-05MG cell lines are heterozygous for BRAF-V600E; A-172, T98G, and U-87MG cell lines are homozygous for wild-type (WT) BRAF. The IC50 values of UI-152 were determined using crystal violet assays. UI-152 displayed the greatest level of selectivity for BRAF-mutant cells, inhibiting their proliferation more potently than that of cells expressing BRAF-WT. The IC50 of UI-152 in B-Raf mutant cells was less than 0.2 μM, whereas the IC50 of cells expressing BRAF-WT were not reached even at 20 μM UI-152. Corresponding immunoblot results showed that UI-152 completely abolished MEK-ERK phosphorylation in DBTRG-05MG cells harboring BRAF-V600E. However, in U-87MG cells expressing BRAF-WT, UI-152 caused the paradoxical activation of the MAPK pathway. UI-152 induced the phosphorylation of MEK/ERK at 5 μM but caused a return to control levels at 10 μM in U-87MG cells. These results indicate that the genetic profile test of glioma is necessary prior to BRAF-targeted therapy to patients. Taken together, our data suggest that UI-152 may be an effective BRAF inhibitor and contribute to a potential therapeutic strategy for brain tumor patients with BRAF mutations. Citation Format: Michael Lee, Jun-Ho Ahn, Soon Kil Ahn, Yong W. Lee. Differential sensitivity of BRAF mutant glioma cell lines to the new oncogenic BRAF kinase inhibitor UI-152. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 940. doi:10.1158/1538-7445.AM2013-940
Electronic cell counting to measure total cell numbers in bronchoalveolar lavage fluid
Authors: LG Heaney, J McKirgan, CF Stanford, M Ennis
Journal: European Respiratory Journal (1994)

Cell counting of bronchoalveolar lavage (BAL) fluid is performed manually in routine practice. This has both methodological and inherent errors; however, the accuracy and suitability of automated counting devices have been questioned. In this study, a Coulter Counter D Industrial model was calibrated and then used to measure the total cell count in unprocessed bronchoalveolar lavage fluid, and compared to a standard manual method. Bronchoalveolar lavage was performed on 34 patients undergoing routine bronchoscopy. An aliquot of unprocessed bronchoalveolar lavage fluid was taken for all counting procedures. Manual counts were performed blind by two experienced independent observers using improved Neubauer chambers. Electronic counting measured 1 ml aliquots suspended in 10 and 20 ml Isoton counting 0.5 and 1 ml duplicates. The correlation coefficients between electronic and manual counts were good. The coefficients of repeatability of electronic counts, for repeat counts, both on the same dilution (Intra-Coulter: 0.1 x 10(5) cells.ml-1) and different dilutions (Interdilution-Coulter: 0.48 x 10(5) cells.ml-1), were superior compared to those for repeat manual counts by the same observer (1.03 x 10(5) cells.ml-1), and counts between observers (1.82 x 10(5) cells.ml-1). This method offers a quick, precise and simple method for counting cells in unprocessed bronchoalveolar lavage fluid, which is both less labour intensive and subjective than manual counting.
A10.8 Evaluation of Disease Activity in Adult Patients with Juvenile Idiopathic Arthritis
Authors: Bulina Inita, Zepa Julija, Astica Ineta, Sikora Evita, Abelite Sarmite, Lavrentjevs Vladimirs, Andersone Daina
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Juvenile idiopathic arthritis (JIA) is a disease which maintains specific childish rheumatological features during whole life. There is still an open discussion which criteria of the disease activity should be used for the management of adult patients with JIA. <h3>Objectives</h3> To analyse the usefulness of known disease activity and functional indices used in adult rheumatological practise for the assessment of rheumatoid arthritis (RA) and spondyloarthritidies (SpA): disease acitivity score (DAS), disease acitivity score 28 (DAS28), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Spondylitis Functional Index (BASFI), Health Assessment Questionnaire – disability index (HAQ-DI), short form health survey with 36 questions (SF-36). <h3>Methods</h3> 35 adult patients with JIA (polyarticular form) classified by the ILAR (International League of Asociations for Rheumatology) classification criteria (Durban 1997, Edmonton 2001) were assessed clinically initially (I) and after 1 year (II) using DAS, DAS28, BASDAI, BASFI, HAQ-DI, SF-36. <h3>Results</h3> 35 adult patients with JIA (polyarticular form) 19.4 (SD 1.8) years old with disease duration 6.5 (SD 4.2). 16 patients receive anti-TNF therapy and 19 patients methotrexate monotherapy. DAS 28 (I) 3.10 (IQR = 2.2) and DAS28 (II) 3.09 (IQR = 1.7), p = 0.3; DAS (I) 2.09 (IQR = 1.6) and DAS (II) 2.03 (IQR = 1), p = 0.39; HAQ-DI (I) 0.44 (IQR = 0.57) and HAQ-DI (II) (IQR = 0.62), p = 0.32; BASDAI (I) 3.6 (IQR = 3.45) and BASDAI (II) 4.75 (IQR = 3.275), p = 0.46; BASFI (I) 1.9 (3.15) and BASFI (II) 1.1 (IQR = 1.2), p = 0.057; SF-36 physical health (I) 40.4 (IQR = 9.5) and SF-36 physical health (II) 38.7 (IQR = 11), p = 0.02; SF-36 mental health (I) 50.1 (IQR = 27) and SF-36 mental health (II) 50.9 (IQR = 14.2), p = 0.6. <h3>Conclusions</h3> Accordingly to the results, increased values of disease activity indices (usually used in adults patients with RA and SpA) show that tendons as well as peripheral joints are involved in the inflammatory process of JIA polyarticular form. Therefore the evaluation of tendons/entheses in adult patients with JIA polyarticular form should be performed routinely in daily rheumatological practise including radiological assessment as well as standard evaluation of peripheral joints. Our data suggest that there is a necessity to create complex index which includes assessment of tendons/entheses/peripheral joints for patients with JIA.
Airway Tissue, But Not Luminal, Eosinophilia Is Related To The Magnitude Of Airway Hyperresponsiveness In a Transgenic Murine Model Of Cat Allergy
Authors: Daniel M. Moldaver, Mantej S. Bharhani, Jennifer Wattie, Tarandeep Singh, Melissa Babra, Marianne van Hage, Mark D. Inman, Mark Larché
Journal: Journal of Allergy and Clinical Immunology (2014)
Mobility for the disabled.
Authors: M A Chamberlain, J Buchanan
Journal: BMJ (1977)

gone and a new system of leadership and decision-making is necessary.Many psychiatrists know that to work in a multidisciplinary team setting does not require the relinquishing of their responsibility and authority.Quite the contrary.In no other situation is skilled leadership more necessary.The intelligent sharing of relevant information and skills in such a setting can be very much to the patient's advantage, leading as it does to action which is carried through with greater insight and motivation just because it was discussed and shared beforehand.I agree that the NHS is crying out for clear medical leadership.But we must ensure that we take our non-medical colleagues with us in a way that recognises their own ability and acknowledges that, from time to time, this may even better our own.
Potentiation of viral carcinogenesis by immunosuppression.
Authors: A. C. Allison
Journal: BMJ (1970)

The role of immunity in controlling the development of tumours may be conveniently analysed by comparing the incidence of tumours induced by viruses in normal animals with that in immunosuppressed animals.The immunosuppressive procedures used have included thymectomy, treatment with antilymphocytic serum, or both.Any of these methods inhibit cell-mediated immunity and have definite effects on the production of tumours by viruses.
Coronary-Artery Stents and Other Endoluminal Devices
Authors: Peter C. Block
Journal: New England Journal of Medicine (1991)

MORE than three years ago, a report was published in the Journal on the use of intravascular stents to prevent occlusion and re-Stenosis after transluminal angioplasty.1 Indications that the principal conclusion of the article was premature arose three months later, when diffuse narrowing was observed in some of the arteries with stents.2 This issue of the Journal contains a report by Serruys et al. on the results of follow-up angiography in 90 percent of the first 105 patients in whom coronary-artery stents were placed (mean follow-up time, 5.7±4.4 months).3 The authors are to be commended for reporting their follow-up results . . .
A plea for reason
Authors: B. Jarman, P. Aylin, A. Bottle
Journal: BMJ (2010)

Many of the arguments in the article by Lilford and Pronovost and the editorial by Black add nothing new to the debate on monitoring the quality of care.1 2 3 We recommend section G and appendix 9 from the Francis inquiry report on Mid Staffordshire for an independent review of these issues.4

The …
Founding mutations and Alu-mediated recombination in hereditary colon cancer
Authors: Minna Nyström-Lahti, Paula Kristo, Nicholas C. Nicolaides, Sheng-Yung Chang, Lauri A. Aaltonen, Anu-Liisa Moisio, Heikki J. Järvinen, Jukka-Pekka Mecklin, Kenneth W. Kinzler, Bert Vogelstein, Albert De La Chapelle, Päivi Peltomäki
Journal: Nature Medicine (1995)
168 EVALUATION OF THE FUNCTIONAL CCL2 PROMOTER POLYMORPHISM −2518A&gt;G AS RISK FACTOR FOR SPONTANEOUS BACTERIAL PERITONITIS AND DEATH IN DECOMPENSATED LIVER CIRRHOSIS
Authors: F. Grünhage, B. Appenrodt, M. Gentenmann, L. Thyssen, S. Schwartz, T. Sauerbruch, F. Lammert
Journal: Journal of Hepatology (2010)
Treatment of stable angina of effort with verapamil: a double-blind, placebo-controlled randomized crossover study.
Authors: S J Brodsky, S S Cutler, D A Weiner, C H McCabe, T J Ryan, M D Klein
Journal: Circulation (1982)

The effects of verapamil were assessed in 26 patients with stable exertional angina pectoris in a double-blind, placebo-controlled, randomized crossover protocol using serial treadmill tests. Verapamil, 480 mg/day, reduced anginal frequency from 5.6 +/- 7.3 to 2.2 +/- 3.9 attacks per week (p less than 0.001) and nitroglycerin consumption from 3.4 +/- 4.9 to 1.2 +/- 2.5 tablets per week (p less than 0.05) compared with placebo. Treadmill time increased from 6.4 +/- 2.1 minutes during the placebo phase to 7.5 +/- 1.8 minutes during the verapamil phase (p less than 0.001). Verapamil's beneficial effect appeared to be related, in part, to a 10% reduction of the rate-pressure product at rest (p less than 0.05) and a 12% reduction during submaximal exercise (p less than 0.001). Verapamil also caused less marked ST-segment depressions at peak exercise (p less than 0.05) at a similar rate-pressure product, suggesting a favorable redistribution of coronary blood flow to the ischemic zone. Side effects from verapamil were minimal, consisting mainly of constipation (six patients). Verapamil appears to be a safe and effective drug for treating angina of effort.
Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study
Authors: R. J. Campbell, S. S. Gill, S. E. Bronskill, J. M. Paterson, M. Whitehead, C. M. Bell
Journal: BMJ (2012)

<b>Objective</b> To assess the risk of systemic adverse events associated with intravitreal injections of vascular endothelial growth factor inhibiting drugs. <b>Design</b> Population based nested case-control study. <b>Setting</b> Ontario, Canada. <b>Participants</b> 91 378 older adults with a history of physician diagnosed retinal disease identified between 1 April 2006 and 31 March 2011. Cases were 1477 patients admitted to hospital for ischaemic stroke, 2229 admitted for an acute myocardial infarction, 1059 admitted or assessed in an emergency department for venous thromboembolism, and 2623 admitted for congestive heart failure. Event-free controls (at a ratio of 5:1) were matched to cases on the basis of year of birth, sex, history of the outcome in the previous 5 years, and diabetes. <b>Main exposure measure</b> Exposure to vascular endothelial growth factor inhibiting drugs identified within 180 days before the index date. <b>Results</b> After adjustment for potential confounders, participants who had ischaemic stroke, acute myocardial infarction, congestive heart failure, or venous thromboembolism were not more likely than control participants to have been exposed to either bevacizumab (adjusted odds ratios of 0.95 (95% confidence interval 0.68 to 1.34) for ischaemic stroke, 1.04 (0.77 to 1.39) for acute myocardial infarction, 0.81 (0.49 to 1.34) for venous thromboembolism, and 1.21 (0.91 to 1.62) for congestive heart failure) or ranibizumab (adjusted odds ratios 0.87 (0.68 to 1.10) for ischaemic stroke, 0.90 (0.72 to 1.11) for acute myocardial infarction, 0.88 (0.67 to 1.16) for venous thromboembolism, and 0.87 (0.70 to 1.07) for congestive heart failure). Similarly, a secondary analysis of exclusive users of bevacizumab or ranibizumab showed no differences in risk between the two drugs (adjusted odds ratios for bevacizumab relative to ranibizumab of 1.03 (0.67 to 1.60) for ischaemic stroke, 1.23 (0.85 to 1.77) for acute myocardial infarction, 0.92 (0.51 to 1.69) for venous thromboembolism, and 1.35 (0.93 to 1.95) for congestive heart failure). These findings were consistent for all but one outcome in subgroup analyses. <b>Conclusions</b> Intravitreal injections of bevacizumab and ranibizumab were not associated with significant risks of ischaemic stroke, acute myocardial infarction, congestive heart failure, or venous thromboembolism.
Accessory Spleen in Hodgkin's Disease
Authors: James M. Jacobson
Journal: JAMA (1978)

STAGING laparotomy and splenectomy commonly are used in the evaluation of Hodgkin's disease. However, to the best of our knowledge, there are no reports in the literature of the dilemma encountered when a patient with Hodgkin's disease postoperatively has a functioning accessory spleen. We report the case of such a patient and discuss the role of the accessory spleen in patients with Hodgkin's disease. <h3>Report of a Case</h3> A 19-year-old man was hospitalized for evaluation of left cervical adenopathy and splenomegaly. A biopsy specimen of a left posterior cervical node was interpreted as showing Hodgkin's disease, mixed cell type. Chest roentgenograms showed a widened mediastinum. Hepatosplenomegaly was demonstrated by a sodium pertechnetate Tc 99m isotope scan. Bone marrow biopsy specimens of the left posterior iliac crest were normal. Bilateral lower extremity lymphangiography results were interpreted as showing possible bilateral abnormalities in the para-aortic regions between the second and fifth lumbar
Iron and copper promote modification of low density lipoprotein by human arterial smooth muscle cells in culture.
Authors: J W Heinecke, H Rosen, A Chait
Journal: Journal of Clinical Investigation (1984)

Modification of low density lipoproteins by human arterial smooth muscle cells was characterized by increased electrophoretic mobility and increased content of malondialdehyde-like oxidation products reactive with thiobarbituric acid. Lipoprotein modification was promoted by micromolar concentrations of iron or copper in the culture medium and was metal ion concentration- and time-dependent. The ability of diverse media to promote smooth muscle cell-mediated low density lipoprotein modification correlated with their iron concentration. Therefore, metal ion concentration of culture media contributes substantially to low density lipoprotein modification in vitro. Human monocyte-derived macrophages took up and esterified the cholesterol from modified low density lipoprotein more extensively than from native low density lipoprotein. Metal ion-mediated modification of low density lipoprotein may be a contributing factor to the pathogenesis of arteriosclerosis.
Transient Ischemia Does Not Limit Subsequent Ischemic Regional Dysfunction in Humans: A Transesophageal Echocardiographic Study During Minimally Invasive Coronary Artery Bypass Surgery
Authors: Michael J Malkowski, Christopher M Kramer, Seyed Taher Parvizi, Sinda Dianzumba, Jose Marquez, Nathaniel Reichek, James A Magovern
Journal: Journal of the American College of Cardiology (1998)
Sequences of complementary DNAs that encode the NA1 and NA2 forms of Fc receptor III on human neutrophils.
Authors: P A Ory, M R Clark, E E Kwoh, S B Clarkson, I M Goldstein
Journal: Journal of Clinical Investigation (1989)

Two polymorphic forms of Fc receptor III (FcR III) are expressed on human neutrophils. These differ with respect to their apparent molecular masses after digestion with N-glycanase, and with respect to their reactivity with MAb Gran 11 and alloantisera which recognize determinants (NA1 and NA2) of the biallelic neutrophil antigen (NA) system. To determine the molecular basis for this polymorphism we isolated RNA from neutrophils of NA1NA1 and NA2NA2 homozygotes and synthesized corresponding cDNAs. cDNAs encoding FcR III were then amplified using the polymerase chain reaction, cloned, and sequenced. The cDNA that encodes FcR III on NA1NA1 neutrophils differed from the cDNA that encodes FcR III on NA2NA2 neutrophils at five nucleotides, predicting four amino acid substitutions. As a result, NA1 FcR III has only four potential N-linked glycosylation sites as compared with six in NA2 FcR III. The amino acid substitutions and differences in the number of potential N-linked glycosylation sites probably account for the different forms of neutrophil FcR III observed after digestion with N-glycanase and for the antigenic heterogeneity of this receptor.